Drugs / IBI397
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05245916 | Apr 2022 → Aug 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI397 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245916 ↗ |